Interest in cannabinoid pharmacology increased dramatically upon the identifi cation of the fi rst cannabinoid receptor (CB1) in 1998 and continues to expand as additional endocannabinoids and cannabinoid receptors are discovered. Using CB1 receptor (CB1R) systems, medicinal chemistry programs began screening libraries searching for cannabinoid ligands, ultimately leading to the discovery of the fi rst potent cannabinoid receptor antagonist, SR141716A (Rimonabant). Its demonstrated effi cacy in treating obesity and facilitating smoking cessation, among other impressive pharmacological activities, has furthered the interest in cannabinoid receptor antagonists as therapeutics, such that the number of patents and publications covering this class of compounds continues to grow at an impressive rate. At this time, medicinal chemistry approaches including combinatorial chemistry, conformational constraint, and scaffold hopping are continuing to generate a large number of cannabinoid antagonists. These molecules provide an opportunity to gain insight into the 3-dimensional structure-activity relationships that appear crucial for CB1R-ligand interaction. In particular, studies in which conformational constraints have been imposed on the various pyrazole ring substituents of SR141716A provide a direct opportunity to characterize changes in conformation/ conformational freedom within a single class of compounds. While relatively few conformationally constrained molecules have been synthesized to date, the structureactivity information is often more readily interpreted than in studies where entire substituents are replaced. Thus, it is the focus of this mini-review to examine the structural properties of SR141716A, and to use conformationally constrained molecules to illustrate the importance of conformation and conformational freedom to CB1R affi nity, selectivity, and effi cacy.
A BSTRACT
Interest in cannabinoid pharmacology increased dramatically upon the identifi cation of the fi rst cannabinoid receptor (CB1) in 1998 and continues to expand as additional endocannabinoids and cannabinoid receptors are discovered. Using CB1 receptor (CB1R) systems, medicinal chemistry programs began screening libraries searching for cannabinoid ligands, ultimately leading to the discovery of the fi rst potent cannabinoid receptor antagonist, SR141716A (Rimonabant). Its demonstrated effi cacy in treating obesity and facilitating smoking cessation, among other impressive pharmacological activities, has furthered the interest in cannabinoid receptor antagonists as therapeutics, such that the number of patents and publications covering this class of compounds continues to grow at an impressive rate. At this time, medicinal chemistry approaches including combinatorial chemistry, conformational constraint, and scaffold hopping are continuing to generate a large number of cannabinoid antagonists. These molecules provide an opportunity to gain insight into the 3-dimensional structure-activity relationships that appear crucial for CB1R-ligand interaction. In particular, studies in which conformational constraints have been imposed on the various pyrazole ring substituents of SR141716A provide a direct opportunity to characterize changes in conformation/ conformational freedom within a single class of compounds. While relatively few conformationally constrained molecules have been synthesized to date, the structureactivity information is often more readily interpreted than in studies where entire substituents are replaced. Thus, it is the focus of this mini-review to examine the structural properties of SR141716A, and to use conformationally constrained molecules to illustrate the importance of conformation and conformational freedom to CB1R affi nity, selectivity, and effi cacy.
INTRODUCTION
With the discovery of the diarylpyrazole CB1 receptor (CB1R) antagonist/inverse agonist SR141716A (Rimonabant or Accomplia), researchers obtained a long-awaited and highly desirable molecular tool with which to further explore cannabinoid receptor function and signal transduction mechanisms. The remarkable phase 3 studies with SR141716A, demonstrating effi cacy in both smoking cessation and obesity trials in humans, has continued to heighten interest in this class of compounds. 1 Several hundred analogs of SR141716A have since been designed, synthesized, and tested in a plethora of pharmacological assays, and compounds are continuing to be described with improved affi nities, varying effi cacies, differing receptor selectivities or unique pharmacological properties and clinical applications (see recent reviews by Muccioli and Lambert, 2 Padgett, 3 and Lange and Kruse 4 ). These studies have helped characterize the conformational properties of SR141716A and the structure-activity relationships of cannabinoid antagonists and inverse agonists. Of particular relevance to the determination of the conformational requirements for receptor binding, receptor selectivity, and effi cacy are studies where conformational constraints have been imposed on the various pyrazole ring substituents of SR141716A. Such studies can often defi ne key conformational properties and relate changes in conformation/conformational freedom to ligand-receptor binding and G-protein coupling.
There are 4 torsion angles of rotation in SR141716A that can represent most of its key conformational characteristics ( Figure 1 ). Using quenched molecular dynamics simulations, it was possible to discern and compare the variety of conformational energies allowed by the structure of the molecule. For example, Figure 2 shows that for the torsion t 1 , the molecule is confi ned energetically to an s-trans confi guration of the carboxamide oxygen group as it connects to the pyrazole. While other conformational minima are possible,
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they are of considerably higher energy [~40 kJ/mol]. Torsion t 2 describes the orientation of the amino-piperidine ring and reveals that 4 energetically preferred geometries exist, with torsion values of ~60º, 120º, 240º, and 300º. With these conformations, the energy differences are such that all 4 conformations are equally likely, but the symmetry of the piperidine ring makes the 60º and 240º, and the 120º and 300º conformations, identical. Despite this symmetry, this torsion angle, combined with the fl exibility of the piperidine ring substituent, represents one of the areas of greatest conformational freedom for this molecule. The other 2 ring substituents are rigid aromatic ring systems, with each aryl substituent having 4 low energy conformations: torsion t 3 ' s energy minima are at ~40º, 140º, 220º, and 320º; t 4 ' s energy minima are at ~60º, 120º, 240º, and 300º. Because of the symmetry of the p -chloro ring system, the t 4 torsion angle at 60º is equivalent to 240º, and 120º is the equivalent of 300º. These 2 torsion angles, t 3 and t 4 , are " cogged, " such that if t 4 is at 60º/240º, t 3 falls into energy minima at 40º or 220º, but if t 4 is at 120º/300º, t 3 has its energy minima at 140º and 320º. These interdependent conformational characteristics are quite apparent from the molecular dynamics simulations, and the energy plot obtained through a grid search of these 2 torsion angles ( Figure 3 ). In the 3-dimensional plot, the 2 torsions have energetically unfavorable interactions when the torsion angles result in coplanar ring systems with one another (any combination of 0º or 180º). Of interest, t 4 appears to be the most energetically constrained system, despite its lacking the larger chlorine substituent in the ortho position as in the t 3 system, pointing to a steric effect of the lone methyl group substituent on the pyrazole ring.
Using x-ray crystallography, s-trans geometry of t 1 was observed in SR141716A crystals (telephone conversation from Clifford George, June, 2004), 5 as it was in crystals of an aryl ring constrained analog of SR141716A synthesized in our laboratory. 6 The importance of the carboxyhydrazine heteroatoms and the trans confi guration of t 1 in SR141716A for recognition and inverse agonist activity has been investigated by Reggio and colleagues through the use of molecular modeling, conformationally restricted analogs, and sitedirected mutagenesis. 5 Molecular modeling and receptor docking studies suggested a critical interaction with lysine K3.28(192) and this substituent. Based on this hypothesis, synthesis of a vinyl-cyclohexyl analog and 4 additional compounds differing in the presence, the orientation, or both of potential hydrogen-bond forming heteroatoms was performed. In studies using wild-type receptors, the binding affi nity of the vinyl-cyclohexyl SR141716 analog (VCHSR) was reduced as compared with SR141716A. A similar decrease in binding affi nity was observed with SR141716A when the lysine K3.28 was mutated to a nonhydrogen bonding residue (K3.28A) in the CB1R. However, an additive effect (or greater) was not observed when the VCHSR analog was tested in the K.328A mutation, consistent with a single (H-bonding) interaction between the carboxyhydrazine and the K3.28(192) residue. Although their modeling results suggest that it is the carboxamide oxygen of SR141716A that interacts with K3.28(192), the mutant cycle calculations could not identify the specifi c K3.28(192) hydrogen bonding site within the C3 substituent of SR141716A. It does seem apparent that the piperidine nitrogen is not necessary for high affi nity binding, because the cyclohexyl analog has been shown to possess affi nity similar to SR141716A. The authors further hypothesized that hydrogen bonding of the SR141716A C3 substituent with K3.28 is responsible for its higher affi nity for the inactive receptor state, leading to its inverse agonism. Consistent with this hypothesis, VCHSR acted as a neutral antagonist at the wild-type CB1R. Additional conformational constraint and structural modifi cations of this region were recently reported. 7 Of interest, these molecules constrained the carboxyamide oxygen atom in the s-cis position and still retained reasonable affi nities. The most analogous molecule to SR141716A, compound 2b ( Figure 4 ) , which has only hydrogen bond accepting capability, exhibited surprisingly high affi nities despite the poor overlap of the piperidinyl groups in the low-energy conformer of SR141716. These results suggest that this analog may bind differently than SR141716 in hCB1-R, with the piperidinyl group in 2b occupying a separate hydrophobic pocket, distinct from that for the 1-piperidinyl group in SR141716, and the hydrogen bond accepting groups forming different networks of hydrogen bond interactions. Alternatively, the conformationally constrained molecules may induce conformational changes in the receptor to accommodate the piperidinyl rings in the same hydrophobic pocket as well as allow alternative hydrogen bond formation.
Ring constraint of torsion t 2 has not been fully characterized. Instead, investigators have often elected to replace the piperidinyl ring system entirely. Even though the plane of symmetry in the piperidine ring simplifi es the system, it is relatively fl exible and can occupy an extended area of space . This approach involves molecular dynamics simulations on each energy-minimized analog at 2000°K. During the molecular dynamics simulation, the molecule was heated from 0°K to 2000°K at 100°K steps lasting 10 picoseconds each, with snapshot conformations taken at 10-ps intervals. Upon reaching 2000°K, the molecule was held at this temperature for 1000 ps, while additional snapshots were acquired at 10-ps intervals. Each of the snapshot conformations obtained for a particular analog was energy minimized again using a conjugate gradient of 0.01 kcal/mol or a maximum of 100 000 iterations as termination criteria, yielding a group of 139 energy-minimized conformers per compound. After these simulations had been performed, all conformations from each of the analogues were overlaid using a single template molecule. Because the pyrazole ring system of SR141716 had a reasonably close corresponding central ring system in most of the analogues, the pyrazole ring atoms were used for atom-by-atom root mean square distance minimization. This alignment positioned all of the molecules in the same 3-dimensional space and superposed the central ring systems to as great an extent as possible.
through several conformational minima. Thus, it remains to be determined if there is a benefi t to be gained by reducing the conformational mobility of this particular substituent, an approach that might be considered promising, because modifi cation of this system has been shown to produce large changes in affi nity as well alter receptor selectivity between CB1 and CB2. 6 , 8-11 While t 3 has 4 low energy torsion angles, and t 4 has only 2 due to symmetry, these ring systems show coordinated movement such that modifi cations of the conformational freedom of one system typically have some implicit or quantifi able effect on the other. In addition, because of the symmetry of the molecule, several low energy nonsuperimposable mirror image conformations are possible, and these are not necessarily equivalent with regard to biological activity. It is possible that the chiral environment of the receptor binding site may preferentially permit high affi nity interactions with only one of the mirror image conformations. Thus, constraint of these 2 aryl ring systems would be expected to provide additional information as to the nature of the interaction of these rings with the CB1R. Coplanarity of the diaryl ring systems can be forced via the structure shown in Figure 5 . This molecule was synthesized in our laboratory via a photocyclization reaction. 6 Its reduced affi nity suggests that coplanarity is not an optimal confi guration of the systems for interaction with CB1R, and/or that the o -chlorine contributes to the high affi nity of SR141716A. An alternative approach to constrain t 4 involved fusing the central pyrazole group of SR141716A with its 5-(4-chlorophenyl) to form a central indazole ring ( Figure 6 ). 12 However, this molecule does not constrain the overall geometry or conformation of the monochloro ring to a position that closely approximates that occupied by the same ring in SR141716A; thus its relatively low affi nity (~500 nM) cannot be solely attributed to constraining the ring in the plane of the pyrazole. It would be interesting to examine additional analogs, such as the one proposed in Figure 6 , to better approximate the structure of SR141716A. The Stoit, 13 Mussinu, 11 and Murineddu 14 , 15 research groups used carbon bridges to reduce the conformational mobility of t 4 ( Figure 7 , Table 1 ). Initially, Stoit et al 13 reported the 3 carbon-bridged compound and found that it had lower affi nity for the CB1R than SR141716A. However, Pinna and colleagues 11 , 13 , 14 varied the bridge length from 1 carbon to 3 carbons and reported that the 3 carbon bridged compound, NESS-0327, had fentomolar (fM) affi nity as compared with the nanomolar (nM) affi nity of SR141716A. Despite the large discrepancy between affi nities, each group ascribed the changes in affi nity to the conformational differences of the molecules as compared with those of SR141716A. Thus, in this particular instance, any interpretation must be tempered by the need to establish a more robust, reproducible estimation of the affi nity and activity of these compounds, particularly the 3 carbon-bridged 6 Note the x-ray shows the transconfi guration of t 1 . 2006; 8 (4) Article 76 (http://www.aapsj.org) .
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from the 1 to the 2 carbon-bridged compounds, particularly as the o -chlorine tries to pass by the p -chloro-substituted ring system, there is still a clear path for this transition that is below 40 kJ/mol. Finally, the barrier grows even further when the 3 carbon bridge is in place. Even here, however, there appears to be a path for transition (saddle point) at ~40 kJ/mol, so that t 3 is in equilibrium across the full range of rotation at room temperature.
The effects on affi nity and potency observed with these bridged compounds deserve further mention. First, the 1 carbon-bridged compound has signifi cantly lower affi nity (equilibrium dissociation constant (K i ) of ~2000 nM) than SR141716A (K i of ~1 nM), or when the aryl rings are fused as in the pyrazole [1,5 f] phenanthridine analog (K i ~50 nM). 6 Thus, constraining the rotation of t 4 with the 1 carbon bridge, so that the ring is in the plane of the pyrazole ring system, is detrimental to binding affi nity. However, if the constraint of t 4 is done by forming the pyrazole [1,5 f] phenanthridine analog, the additional constraint of t 3 appears to attenuate the decrease in affi nity seen with the 1 carbonbridged molecule. Second, in the 2 carbon-bridged compound, t 4 has somewhat greater fl exibility and deviates from coplanarity with the pyrazole ring, and t 3 can still freely rotate at room temperature; the affi nity of this compound is intermediate (~14 nM). Finally, in the 3 carbonbridged molecule, t 3 can obtain positions similar to those available for SR141716A, and t 4 can access all of the energy minima at torsions also in close proximity to the minimum energy torsion angles for SR141716A. Thus, based on similarity of conformational shape to SR141716A, it might be expected that the 3 carbon-bridged analog would have similar affi nity to SR141716A. However, if the conformational constraint restrains the ring system to a bioactive conformation around t 4 , a more potent compound would be anticipated. Alternatively, a less potent compound would be anticipated if t 4 and t 3 were being constrained to angles outside of the bioactive conformation, which would still be quite energetically accessible with SR141716A ' s free rotation of t 4 . Because the barrier for free rotation does not exceed 40 kJ/mol, a compound of roughly the same affi nity might be expected. However, the fact that 2 laboratories molecule. It is interesting to note that the research reported by Stoit et al 13 included in vivo administration of the 3 carbon-bridged compound by intraperitoneal (ip) and oral (po) routes, and the authors reported that no activity was detected, which would be more consistent with a compound that had decreased affi nity as compared with SR141716A. However, it is not clear in their report what measures of pharmacological activity were measured, and as the authors pointed out, the bioavailability of the compounds could be quite different. Regardless of these diffi culties, the conformational considerations of these bridged compounds are quite interesting.
As shown in Figure 8 , with 1 carbon atom as the bridge, the t 4 torsion angle is drastically reduced in its range of motion, remaining almost coplanar with the pyrazole ring system. There is little range for torsional changes of t 4 , and the energy minima on each side are equivalent. Of interest, the one carbon-bridged molecule appears to pull the p -chloro-substituted aryl ring away from the dichloro aryl ring system, allowing free rotation across the entire 360 range of t 3. The energy manifold shows a small energy barrier resulting from proton-proton steric interactions, and a somewhat larger energy barrier resulting from protonchlorine interactions; however, these energy barriers are below 40 kJ/mol. Increasing the bridging carbon atoms to 2 appears to push the aryl ring systems closer together, making it energetically more diffi cult for t 3 to rotate through its entire range. While it is clear that the energy barrier increases 
CONCLUSION
The conformational properties of SR141716A are readily modeled and have been further characterized by the use of conformational constraint. However, the degree of conformational constraint that has been described to date has not been extensive. Some studies have indicated that the s-trans confi guration of the amino-piperidine ring substituent is important in hydrogen bonding with the cannabinoid receptor, while others have illustrated the importance of the orientation of the aryl ring systems. Still, while some systematic changes in the conformation of the monochloro ring system have been imposed and tested, very little is known regarding the conformational considerations involved in the interaction of the dichloro ring system within the cannabinoid receptor binding site(s). It remains to be determined if molecules can continue to be synthesized that impose unique conformational constraints, that when tested, can further defi ne the conformational requirements for optimal interaction with the cannabinoid receptor.
